Aduro Biotech to Present at the 28th Annual Oppenheimer Healthcare Conference

BERKELEY, Calif., March 14, 2018 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 28th Annual Oppenheimer Healthcare Conference in New York, NY on Wednesday, March 21, 2018, at 9:10 am Eastern Time.

To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro's website at www.aduro.com.

About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in both a Phase 1 monotherapy study as well as a Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal antibody platform is comprised of a number of immune modulating assets in research and development, including BION-1301, an anti-APRIL antibody. Aduro's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neoantigens that are specific to an individual patient’s tumor. Other Listeria strains for lung and prostate cancers are being advanced by a partner. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.

Contact:                                                                       
Jennifer Lew                                                                
Chief Financial Officer                                                            
510 809-4816   

Media Contact:   
Aljanae Reynolds
510 809 2452                                                  
[email protected]